Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?

Citació

  • Rodriguez E, Barrios C, Soler MJ. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?. Clin Kidney J. 2017 Jun;10(3):320-322. DOI: 10.1093/ckj/sfx024

Enllaç permanent

Descripció

  • Resum

    Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.
  • Mostra el registre complet